An artificial intelligence technique for detecting DNA fragments shed by tumors and circulating in a patient’s blood, developed by Johns Hopkins Kimmel Cancer Center investigators, could help clinicians more quickly identify and determine if pancreatic cancer therapies are working.
FDA rolled out a generative artificial intelligence tool designed to help employees across the agency “work more efficiently.”
